Bausch + Lomb (NYSE:BLCO) Price Target Raised to $22.00

Bausch + Lomb (NYSE:BLCO) had its price target upped by JPMorgan Chase & Co. from $16.00 to $22.00 in a research note published on Thursday,Benzinga reports. They currently have a neutral rating on the stock.

Several other research firms have also recently weighed in on BLCO. Barclays upgraded shares of Bausch + Lomb to a “strong-buy” rating in a research report on Wednesday, October 7th. Royal Bank Of Canada boosted their target price on shares of Bausch + Lomb from $21.00 to $23.00 and gave the company an “outperform” rating in a report on Thursday. Evercore set a $17.00 price target on shares of Bausch + Lomb in a research report on Monday, July 6th. Leerink Partners assumed coverage on Bausch + Lomb in a report on Wednesday, September 9th. They set an “outperform” rating and a $24.00 price target for the company. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a report on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $20.75.

Bausch + Lomb Stock Performance

NYSE:BLCO opened at $19.99 on Thursday. The company has a market capitalization of $7.14 billion, a PE ratio of -64.48, a P/E/G ratio of 0.59 and a beta of 0.56. The company has a 50 day simple moving average of $17.35 and a two-hundred day simple moving average of $16.69. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.02 and a current ratio of 1.56. Bausch + Lomb has a fifty-two week low of $14.44 and a fifty-two week high of $21.36.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings results on Wednesday, October 28th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.13. The firm had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.37 billion. Bausch + Lomb had a negative net margin of 2.05% and a positive return on equity of 5.01%. The company’s revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.18 EPS. Research analysts anticipate that Bausch + Lomb will post 0.94 earnings per share for the current year.

Insider Buying and Selling

In other news, CAO Frederick Munsch sold 52,900 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $16.78, for a total transaction of $887,662.00. Following the completion of the sale, the chief accounting officer owned 45,831 shares of the company’s stock, valued at $769,044.18. This trade represents a 53.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Eschenbach Andrew C. Von sold 12,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $16.50, for a total transaction of $206,250.00. Following the sale, the director directly owned 69,792 shares of the company’s stock, valued at approximately $1,151,568. This trade represents a 15.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 71,459 shares of company stock worth $1,194,370 over the last 90 days. Company insiders own 1.45% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. State of Wyoming increased its stake in Bausch + Lomb by 6.9% in the third quarter. State of Wyoming now owns 13,772 shares of the company’s stock valued at $234,000 after purchasing an additional 887 shares in the last quarter. Beach Point Capital Management LP acquired a new position in shares of Bausch + Lomb during the third quarter valued at about $5,882,000. Counterpoint Mutual Funds LLC acquired a new position in shares of Bausch + Lomb during the third quarter valued at about $670,000. Roxbury Financial LLC bought a new position in shares of Bausch + Lomb during the 3rd quarter worth about $33,000. Finally, Engineers Gate Manager LP bought a new position in shares of Bausch + Lomb during the 2nd quarter worth about $1,479,000. 11.07% of the stock is owned by institutional investors.

Trending Headlines about Bausch + Lomb

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Strong quarterly results: Bausch + Lomb reported adjusted earnings of $0.34 per share, well above the $0.21 consensus estimate, while revenue reached approximately $1.38 billion versus expectations of $1.37 billion. Revenue increased 7.3% year over year. Bausch + Lomb Q3 2026 Earnings
• Positive Sentiment: Higher 2026 guidance: Management raised its forecast to $5.450 billion-$5.550 billion in revenue and $1.090 billion-$1.140 billion in adjusted EBITDA, citing continued momentum from its Vision ’27 strategy. The improved outlook supports investor confidence in growth and profitability. Bausch + Lomb Raises 2026 Guidance
• Positive Sentiment: Analysts raised targets: RBC lifted its price target from $21 to $23 and maintained an “outperform” rating. JPMorgan raised its target from $16 to $22, although it retained a “neutral” rating. The revisions indicate that analysts see improved earnings potential following the results. RBC Raises BLCO Price Target
• Neutral Sentiment: Deutsche Bank raised its target from $16 to $20 but kept a “hold” rating, while Wells Fargo increased its target from $18 to $19 and maintained an “equal weight” rating. These calls reflect more cautious views after the stock’s recent advance. Deutsche Bank Adjusts BLCO Price Target

Bausch + Lomb Company Profile

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.